ArticleExperimental and therapeutic medicine2017
Combination of alendronate and genistein synergistically suppresses osteoclastic differentiation of RAW267.4 cells
Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 7 citations in OpenAlex.
- The Early Effect of Alendronate, Hop Extract and Their Combination on Bone Structural Properties in a Rat Model of Osteoporosis.Medical sciences (Basel, Switzerland) · 2026Article
- Phenolic-derived compounds in osteoporosis-Mechanisms, clinical evidence, and drug delivery: A review.Biomolecules & biomedicine · 2025Review
- Endophytic fungi from Cissus quadrangularis plant a promising source of bioactive compounds.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- The protective activity of genistein against bone and cartilage diseases.Frontiers in pharmacology · 2022Review
- Emerging Natural-Product-Based Treatments for the Management of Osteoarthritis.Antioxidants (Basel, Switzerland) · 2021Review
- Suppression Effect of Astaxanthin on Osteoclast Formation In Vitro and Bone Loss In Vivo.International journal of molecular sciences · 2018Article
- Bone Health and Natural Products- An Insight.Frontiers in pharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone is a dynamic tissue that undergoes constant remodeling, with removal by osteoclastic bone resorption and replacement via osteoblastic bone formation and mineralization. Deterioration of bone mass with aging leads to osteoporosis. Bisphosphonates are potent inhibitors of osteoclastic bone resorption. Genistein, an isoflavone, exerts a bone anabolic effect by suppressing osteoclastic bone resorption and stimulating osteoblastic bone formation. The present study was undertaken to investigate the anabolic effects of a combination of alendronate and genistein on osteoclastic differentiation. Preosteoclastic RAW267.4 cells were cultured with alendronate (0.1-100 µM) and/or genistein (0.1-100 µM)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.